India · Delayed Price · Currency is INR Onyx Biotec Statistics
Total Valuation
Onyx Biotec has a market cap or net worth of INR 675.42 million. The enterprise value is 786.76 million.
| Market Cap | 675.42M |
| Enterprise Value | 786.76M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Onyx Biotec has 18.13 million shares outstanding. The number of shares has increased by 21.03% in one year.
| Current Share Class | 18.13M |
| Shares Outstanding | 18.13M |
| Shares Change (YoY) | +21.03% |
| Shares Change (QoQ) | +1.36% |
| Owned by Insiders (%) | 65.10% |
| Owned by Institutions (%) | n/a |
| Float | 6.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.97 |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.13 |
| EV / EBITDA | 23.02 |
| EV / EBIT | 215.49 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.58 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 4.44 |
| Debt / FCF | n/a |
| Interest Coverage | 0.30 |
Financial Efficiency
Return on equity (ROE) is -0.39% and return on invested capital (ROIC) is 0.55%.
| Return on Equity (ROE) | -0.39% |
| Return on Assets (ROA) | 0.24% |
| Return on Invested Capital (ROIC) | 0.55% |
| Return on Capital Employed (ROCE) | 0.58% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.77M |
| Profits Per Employee | -5,455 |
| Employee Count | 393 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 3.50 |
Taxes
| Income Tax | -2.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -11.31% |
| 50-Day Moving Average | 40.46 |
| 200-Day Moving Average | 36.87 |
| Relative Strength Index (RSI) | 45.15 |
| Average Volume (20 Days) | 30,700 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Onyx Biotec had revenue of INR 694.69 million and -2.14 million in losses. Loss per share was -0.12.
| Revenue | 694.69M |
| Gross Profit | 167.12M |
| Operating Income | 3.65M |
| Pretax Income | -4.22M |
| Net Income | -2.14M |
| EBITDA | 34.17M |
| EBIT | 3.65M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 40.37 million in cash and 151.71 million in debt, with a net cash position of -111.34 million or -6.14 per share.
| Cash & Cash Equivalents | 40.37M |
| Total Debt | 151.71M |
| Net Cash | -111.34M |
| Net Cash Per Share | -6.14 |
| Equity (Book Value) | 554.08M |
| Book Value Per Share | 30.56 |
| Working Capital | 187.51M |
Cash Flow
In the last 12 months, operating cash flow was -14.94 million and capital expenditures -49.87 million, giving a free cash flow of -64.81 million.
| Operating Cash Flow | -14.94M |
| Capital Expenditures | -49.87M |
| Depreciation & Amortization | 30.52M |
| Net Borrowing | 27.14M |
| Free Cash Flow | -64.81M |
| FCF Per Share | -3.57 |
Margins
Gross margin is 24.06%, with operating and profit margins of 0.53% and -0.31%.
| Gross Margin | 24.06% |
| Operating Margin | 0.53% |
| Pretax Margin | -0.61% |
| Profit Margin | -0.31% |
| EBITDA Margin | 4.92% |
| EBIT Margin | 0.53% |
| FCF Margin | n/a |
Dividends & Yields
Onyx Biotec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.03% |
| Shareholder Yield | -21.03% |
| Earnings Yield | -0.32% |
| FCF Yield | -9.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Onyx Biotec has an Altman Z-Score of 2.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.38 |
| Piotroski F-Score | 2 |